| Document and Entity Information - USD ($) | 12 Months Ended | ||
| Dec. 31, 2021 | Apr. 25, 2022 | Jun. 30, 2021 | |
| Cover [Abstract] | |||
| Document Type | 10-K/A | ||
| Amendment Flag | true | ||
| Amendment Description | On March 23, 2022, TherapeuticsMD, Inc., a Nevada corporation (the “Company”), filed its Annual Report on Form 10-K for the fiscal year ended December 31, 2021 (the “Original Form 10-K”). The Company is filing this Amendment No. 1 on Form 10-K/A (the “Form 10-K/A”) in order to include the information required by Items 10 through 14 of Form 10-K. This information was previously omitted from the Original Form 10-K consistent with General Instruction G(3) to Form 10-K. The Company is filing the 10-K/A to provide the information required in Part III of Form 10-K for purposes of incorporating that information by reference into other filings with the Securities and Exchange Commission (the “SEC”). This Form 10-K/A amends and restates in its entirety Part III, Items 10 through 14 of the Original Form 10-K, to include information previously omitted from the Original Form 10-K consistent with General Instruction G(3) to Form 10-K. Throughout this Form 10-K/A, the terms “we,” “us,” “our,” “TherapeuticsMD,” or “our Company” refer to TherapeuticsMD, Inc., a Nevada corporation, and unless specified otherwise, include our wholly owned subsidiaries, vitaMedMD, LLC, a Delaware limited liability company, or VitaMed; BocaGreenMD, Inc., a Nevada corporation, or BocaGreen; and through its divestiture on April 14, 2022, VitaCare Prescription Services, Inc., a Florida corporation, or VitaCare. In addition, as required by Rule 12b-15 under the Securities Exchange Act of 1934, as amended (the “Exchange Act”), certifications by the Company’s principal executive officer and principal financial officer are filed as exhibits to this Form 10-K/A pursuant to Section 302 of the Sarbanes-Oxley Act of 2002 (“Sarbanes-Oxley”). Because no financial statements have been included in this Form 10-K/A and this Form 10-K/A does not contain or amend any disclosure with respect to Items 307 and 308 of Regulation S-K, paragraphs 3, 4 and 5 of the Section 302 certifications have been omitted. We are not including the certifications under Section 906 of Sarbanes-Oxley as no financial statements are being filed with this Form 10-K/A. Except as described above, this Form 10-K/A does not modify or update disclosure in, or exhibits to, the Original Form 10-K. Furthermore, this Form 10-K/A does not change any previously reported financial results, nor does it reflect events occurring after the date of the Original Form 10-K. Information not affected by this Form 10-K/A remains unchanged and reflects the disclosures made at the time the Original Form 10-K was filed. Accordingly, this Form 10-K/A should be read in conjunction with the Original Form 10-K and our other filings with the SEC. | ||
| Document Annual Report | true | ||
| Document Transition Report | false | ||
| Document Period End Date | Dec. 31, 2021 | ||
| Document Fiscal Period Focus | FY | ||
| Document Fiscal Year Focus | 2021 | ||
| Current Fiscal Year End Date | --12-31 | ||
| Entity File Number | 001-00100 | ||
| Entity Registrant Name | THERAPEUTICSMD, INC. | ||
| Entity Central Index Key | 0000025743 | ||
| Entity Tax Identification Number | 87-0233535 | ||
| Entity Incorporation, State or Country Code | NV | ||
| Entity Address, Address Line One | 951 Yamato Road, | ||
| Entity Address, Address Line Two | Suite 220 | ||
| Entity Address, City or Town | Boca Raton | ||
| Entity Address, State or Province | FL | ||
| Entity Address, Postal Zip Code | 33431 | ||
| City Area Code | 561 | ||
| Local Phone Number | 961-1900 | ||
| Title of 12(b) Security | Common Stock, par value $0.001 per share | ||
| Trading Symbol | TXMD | ||
| Security Exchange Name | NASDAQ | ||
| Entity Well-known Seasoned Issuer | No | ||
| Entity Voluntary Filers | No | ||
| Entity Current Reporting Status | Yes | ||
| Entity Interactive Data Current | Yes | ||
| Entity Filer Category | Non-accelerated Filer | ||
| Entity Small Business | true | ||
| Entity Emerging Growth Company | false | ||
| Entity Shell Company | false | ||
| Entity Public Float | $ 444,995,626 | ||
| Entity Common Stock, Shares Outstanding | 433,427,878 | ||
| ICFR Auditor Attestation Flag | false | ||
| Auditor Name | Grant Thornton LLP | ||
| Auditor Location | Miami, Florida | ||
| Auditor Firm ID | 248 | ||
| Documents Incorporated by Reference | Documents Incorporated by Reference None |
